Erlotinib Prevent Disease Recurrence in Early Stage EGFR Positive NSCLC Patients? - 100390

Spotlight
Video

Erlotinib Prevent Disease Recurrence in Early Stage EGFR Positive NSCLC Patients?

cancergrace has 1088 videos Subscribe Here

Loading........
Description: http://cancerGRACE.org/...

Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.

GRACEcast 215 Lung
Shared By : cancergrace
Posted on : 05/20/14
Added : 5 years ago